港股異動丨復星醫藥逆勢漲超10%,自研創新藥蘆沃美替尼片雙適應症獲批上市
復星醫藥AH股均逆勢上漲。H股一度漲超10%報16.5港元,成交額放大至超4億港元,股價創去年10月以來新高;A股一度漲超5%,報25.45元。消息面上,復星醫藥宣佈,自主研發的1類新藥蘆沃美替尼片(商品名:復邁寧®;項目代號:FCN-159)正式獲國家藥品監督管理局(NMPA)批準上市。作爲一款高選擇性MEK1/2抑制劑,復邁寧本次獲批的兩項適應症分別用於治療:朗格漢斯細胞組織細胞增生症(LCH)和組織細胞腫瘤成人患者,以及2歲及2歲以上伴有症狀、無法手術的叢狀神經纖維瘤(PN)的I型神經纖維瘤病(NF1)兒童及青少年患者。據悉,這是上海今年第6款獲批上市的國產1類創新藥,也是近期又一款獲批上市的罕見病用藥。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.